Sunpharma stock recommendation huozmoe

Sunpharma stock recommendation

25.01.2021

Meginnes35172

Only 40 per cent of the analysts tracking Sun Pharma’s stock have a buy recommendation on it. Given these circumstances, investors would want the company to disclose more — be it the price paid to settle the US antitrust litigation related to Modafinil drug, or the progress on approvals from its Halol plant, or any related party Sun Pharma Q4: Profit down 52.6 percent at Rs 635.9 crore versus Rs 1,342.5 crore; revenue up 2.7 percent at Rs 7,163.9 crore versus Rs 6,977 crore (YoY). Company absorbed unsold goods worth Rs Get latest Sun Pharma News/Updates and Results/Analysis. Also get Sun Pharma Share/Stock detailed Information on Sun Pharma along with top stories and articles on Sun Pharma during last 6 months. Sun Pharma share price rises 10% as board to consider share buyback. Mar 12, 22:36. Sun Pharma board to consider share buyback plan next week. Mar 09, 21:09. Pharma sales see rebound in February on back of respiratory drugs. Mar 04, 13:03. Top buy and sell ideas by Ashwani Gujral, Sudarshan Sukhani, Mitesh Thakkar for short term

Sun Pharma Advanced Research Company Ltd., incorporated in the year 2006, is a Mid Cap company (having a market cap of Rs 2743.64 Crore) operating in Pharmaceuticals sector. Sun Pharma Advanced Research Company Ltd. key Products/Revenue Segments include Sale of services which contributed Rs 182.87 Crore to Sales Value (100.00 % of Total Sales

Sun Pharma. Share Price Live - 358.20, Sun Pharma. Stock Price, Today - The Economic Times. Buy Sun Pharma, price target Rs 430: Gaurav Ratnaparkhi| Recos. 04 Mar, 2020, 04.57AM Views and Recommendations · Technical Charts It also contains the Live Stock Price and Volume, 52 Week High Low, Bid and Offer Price and Volume, Intraday and Historical Price Chart. Intraday Data not See 35 recent research reports for SUNPHARMA, BSE:524715 Sun to sort reports by date, stock name, broker, price, target, upside or recommendation. SUN PHARMA: Get the latest SUN PHARMA Share price and stock price updates , live NSE/BSE share price, share market reports, financial report, balance

TradingView India. View live SUN PHARMACEUTICAL chart to track its stock's price action. Find market predictions, SUNPHARMA financials and market news.

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding SUN PHARMACEUTICAL is 'Not Rated'.Macroaxis provides SUN PHARMACEUTICAL buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SUNPHARMA positions. Sun Pharmaceutical Industries Ltd (SUNPHARMA:NSI) forecasts: consensus recommendations, research SUNPHARMA:NSI National Stock Exchange of India; Sun Pharmaceutical Industries Ltd. intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation Sun Pharma Inds. Analyst, Brokerage Reports, Latest Research Report on Sun Pharma Inds.. Sun Pharma Inds. Live BSE, NSE Charts, historical charts, F&O Quote, Stock quote of Sun Pharma Inds., Sun Sun Pharmaceutical Industries Ltd is an international specialty pharma company. The company also makes active pharmaceutical ingredients. In branded markets, their products are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, gastroenterology, dialectology and respiratory. SUN PHARMA: Get the latest SUN PHARMA Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com

Stock has jumped by more than 10% in last two weeks from its lowest level of 325.0 dt 13-Mar-20: Share has hit 52 Week high on 13-Mar-20 (Yesterday). Stock has fallen by more than 10% in last two weeks from its highest level of 414.8 dt 05-Mar-20. Stock has fallen by more than 25% in last three Month from its highest level of 462.5 dt 28-Jan-20.

TradingView India. View live SUN PHARMACEUTICAL chart to track its stock's price action. Find market predictions, SUNPHARMA financials and market news. 2 Dec 2019 Shrikant Chouhan recommended to keep a stoploss at Rs 438 . Whenever the stock has seen such a formation, the analyst said it can be 8 Nov 2019 Sun Pharma's net sales for the quarter rose 16.10 per cent to Rs our BUY recommendation on the stock with a Target Price of Rs 500, 11 Jun 2019 Meanwhile, HDFC Securities is bullish on Sun Pharma has recommended a 'buy' rating on the stock with a target price of Rs 600 in its research Industries Limited - SUNPHARMA Important levels,Technical Analysis,Future & Option,Interactive Charts,Short & Long term Stock Recommendation @ 682.55

SUN PHARMA: Get the latest SUN PHARMA Share price and stock price updates , live NSE/BSE share price, share market reports, financial report, balance

Stock has jumped by more than 10% in last two weeks from its lowest level of 325.0 dt 13-Mar-20: Share has hit 52 Week high on 13-Mar-20 (Yesterday). Stock has fallen by more than 10% in last two weeks from its highest level of 414.8 dt 05-Mar-20. Stock has fallen by more than 25% in last three Month from its highest level of 462.5 dt 28-Jan-20. Nevertheless, 87 per cent of the analysts tracking the stock have a buy recommendation. Torrent Pharma, trading at valuations richer than Sun Pharma, is another company with encouraging prospects. Its acquisition of Unichem Labs in the domestic market, and growing business in the US, Germany and Brazil, burnish its allure. Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding SUN PHARMACEUTICAL is 'Not Rated'.Macroaxis provides SUN PHARMACEUTICAL buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SUNPHARMA positions. Sun Pharma Advanced Research Company Ltd., incorporated in the year 2006, is a Mid Cap company (having a market cap of Rs 2743.64 Crore) operating in Pharmaceuticals sector. Sun Pharma Advanced Research Company Ltd. key Products/Revenue Segments include Sale of services which contributed Rs 182.87 Crore to Sales Value (100.00 % of Total Sales